While autologous cell therapies have delivered impressive results, manufacturing is expensive, highly variable, and difficult to scale. They also add logistical hurdles at treatment centers and require space for apheresis and transport of individual patient material, resulting in products often not reaching patients in need. Allogeneic (allo) cell therapies, including CAR-T, are a long-awaited next-generation option addressing many of these challenges. Here, T cells derived from healthy donors as opposed to heavily pretreated patients result in theoretically higher quality products, which may ultimately correlate with superior clinical effect. This discussion will explore the promise of allo cell therapies to broaden patient access, lower costs, and increase reliability and scalability.